yahoo_financeOriginal article
Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease
Phase 3BuntanetapPositive
AI Analysis
Summary
Annovis announced full enrollment in its pivotal Phase 3 trial of Buntanetap for early Alzheimer's disease. This enrollment milestone represents progress toward potential data readout and regulatory submission.
Clinical Trial Data
Phase
3
Outcome Details
Full enrollment achieved
Importance:6/10
Sentiment:
0.70
Phase_3enrollmentAlzheimer'sAnnovisBuntanetap
Related Companies
Read the original article
Published by yahoo_finance on July 7, 2026 11:00 AM